$TPTX on NASDAQ
August 08, 2022
Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates
July 27, 2022
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC
June 24, 2022
Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies
May 26, 2022
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
May 16, 2022
Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer
May 10, 2022
Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates
May 10, 2022
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy
May 05, 2022
Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines
April 28, 2022
Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
April 12, 2022
Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study
March 29, 2022
Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel
March 21, 2022
Turning Point Therapeutics Announces Achievement of Enrollment Goal for TRIDENT-1 NTRK-Positive TKI-Pretreated Advanced Solid Tumor Patients and Plans for Pre-NDA Meeting for This Patient Population
March 09, 2022
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
March 07, 2022
Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference - Update
March 01, 2022
Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference
February 28, 2022
Turning Point Therapeutics Reports Fourth-Quarter and Full Year 2021 Financial Results, Provides Operational Updates
February 02, 2022
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
January 20, 2022
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung Cancer
January 18, 2022
Turning Point Therapeutics Provides Updates and Anticipated 2022 Clinical and Discovery Pipeline Milestones
December 20, 2021
Turning Point Therapeutics Provides Regulatory Updates
November 10, 2021
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
November 09, 2021
Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates
November 08, 2021
Turning Point Therapeutics Announces Appointment of Adam Levy as Senior Vice President of Investor Relations
November 02, 2021
Turning Point Therapeutics to Host Third Quarter 2021 Conference Call
October 23, 2021
Turning Point Therapeutics Presents Early Clinical Data for Repotrectinib From Care Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress
October 13, 2021
Turning Point Therapeutics and EQRx Announce Clinical Collaboration to Evaluate Elzovantinib in Combination with Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung Cancer
October 11, 2021
Turning Point Therapeutics to Present Early Clinical Data for Repotrectinib From the CARE Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress
October 08, 2021
Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference
October 07, 2021
Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates
October 04, 2021
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
September 30, 2021
Turning Point Therapeutics Announces Additional Details for Three Data Presentations at the 2021 AACR-NCI-EORTC Conference
September 08, 2021
Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference
September 01, 2021
Turning Point Therapeutics to Participate In Upcoming Investor Conferences
August 16, 2021
Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors
August 11, 2021
Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib
August 09, 2021
Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates
July 28, 2021
Turning Point Therapeutics to Host Second Quarter 2021 Conference Call
June 29, 2021
Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer
June 17, 2021
Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer
June 01, 2021
Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference
May 25, 2021
Turning Point Therapeutics Names Former Celgene Chairman and CEO, Mark Alles, to Chair Its Board of Directors
May 17, 2021
Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer
May 05, 2021
Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates
April 26, 2021
Turning Point Therapeutics to Host First Quarter 2021 Conference Call
April 12, 2021
Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor
April 09, 2021
Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates
April 05, 2021
Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046
March 31, 2021
Turning Point Therapeutics Announces Board Changes
March 10, 2021
Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting
March 04, 2021
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
- No Recent Filings Found.
